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Available online 13 October 2016Minimodeling is a type of focal bone formation that is characterized by the lack of precedent bone erosion by os-
teoclasts. Although this form of bone formation has been described formore than a decade, how anti-osteoporotic
agents that are currently used in clinical practice affect the kinetics of minimodeling is not fully understood. We
performed a bone morphometric analysis using human vertebral specimens collected from postmenopausal pa-
tients who underwent spinal surgery. Patients were divided into three groups according to osteoporosis
medication; non-treated, Eldecalcitol (ELD, a vitaminDderivative that has recently been approved to treat patients
with osteoporosis in Japan)-treated, and bisphosphonate-treated groups. Five to six patients were enrolled in each
group. There was a trend toward enhancedminimodeling in ELD-treated patients and suppressed of it in bisphos-
phonate-treated patients compared with untreated patients. The differences of minimodeling activity between
ELD-treated and bisphosphonate-treated patients were statistically signiﬁcant. The present study suggests that
ELD and bisphosphonates have opposite effects on minimodeling from one another, and show that minimodeling
also takes place in vertebrae as has been described for the ilium and femoral head in humans.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Osteoporosis is characterized by reduced bone mass and the loss of
microarchitectural integrity in bone tissue, ultimately leading to bone
fragility and increased susceptibility to fracture (Kanis, 1994). Osteopo-
rosis-related fractures in elderly patients severely compromise their
quality of life and activities of daily living (ADL) and impose a major
burden on society and the medical economy, especially in developed
countries (Egermann et al., 2005). Therefore, it is imperative to learn
more about the pathology of and prophylaxis for osteoporosis and oste-
oporosis-related fractures.
Minimodeling is a form of trabeculae modeling and is so termed
based on the miniature nature of this process in vivo (Frost, 1990). In
conventional remodeling, bone formation is preceded by bone resorp-
tion, and, therefore, the cement lines are usually irregularly shaped. In
contrast, in minimodeling, bone formation occurs on quiescent bone
surfaces and thus creates smooth cement lines (Frost, 1990; Jee et al.,
2007; Kobayashi et al., 2003). The nature and function of minimodeling
are not fully understood; however, it is likely to be an adaptiveSurgery, Keio University School
582, Japan.
. This is an open access article undermechanism to strengthen the skeletal microstructure in response to
mechanical stress (Frost, 1990). Past studies have shown that
minimodeling can be enhanced in patients and animals who are treated
with bone anabolic agents, such as PTH (teriparatide) (Lindsay et al.,
2006; Ma et al., 2006) and prostaglandin E2 (Zhou et al., 2001; Yao et
al., 1999). On the other hand, the potential effects of more common
anti-osteoporotic agents, such as vitamin D3 and bisphosphonates
(BPs) on minimodeling in humans have remained unaddressed.
In the present study, we aimed to evaluate the potential effects of a
new vitamin D3 analog, Eldecalcitol (2β-(3-hydroxypropyloxy)-1,25-
dihydroxyvitamin D3, henceforth referred to as ELD), and BPs on
minimodeling in humans using surgical specimens that were collected
frompostmenopausal patients who underwent spinal surgery. In accor-
dance with past reports (Jee et al., 2007; Kobayashi et al., 2003),
minimodeling was readily observed also in the human vertebral speci-
mens that were examined in the present study. Most importantly, we
found that patients who had been treated with ELD prior to surgery
tend to have increased minimodeling activity compared with the con-
trol patients and those treated with BPs. Our data suggest that ELD
potentially activates minimodeling in postmenopausal patients while
BPs have negative or little impact on this form of bone formation,
and that each anti-osteoporotic agents have distinct effects on
minimodeling in vivo.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study design, subjects, and ethics statement
Of the female patients with lumbar degenerative disorder who
underwent lumbar spinal surgery at our institution from October 2012
to July 2014, we enrolled those who conﬁrmed by interview that they
had reached menopause N3 years prior. Patients were excluded if they
had primary hyperparathyroidism; Cushing's syndrome; premature
menopause due to hypothalamic, pituitary or gonadal insufﬁciency,
poorly controlled diabetes mellitus (HbA1c over 8.0%); or other causes
of secondary osteoporosis. Patients were also excluded if they had
taken glucocorticoids or hormone replacement therapy in the past
3 months or had clinically signiﬁcant hepatic, cardiac, or malignant dis-
orders. Sixteenpatientswere eligible for this study. Ten of these patients
were taking osteoporosis medications. Five of these ten patients had
taken BPs (BP group), while the other ﬁve had solely taken ELD (ELD
group), for N6months. Six patients had no history of osteoporosis med-
ication (Ctrl group). Bone specimens were collected from the lamina of
the lumbar vertebra that was removed during surgery. The present
study was approved by the Institutional Review Board of KeioFig. 1.Minimodeling sites on trabeculae. Conventional (a), polarized (b), and ﬂuorescent (c) ligh
specimen from a 75-year-old woman who underwent lumbar decompression surgery for lum
minimodeling site (left panels); whereas, no apparent osteoid is found in the quiescent min
minimodeling; QMI, quiescent minimodeling; SCL, smooth cement line; SCL scalloped cementUniversity School of Medicine (approval number, 20,130,109) and in-
formed consent was obtained from each patient.
2.2. Measurement of BMD
The BMD of the L2-L4 vertebrae and bilateral femurs was measured
prior to surgery by dual-energy X-ray absorptiometry (Prodigy; GE
Healthcare, Tokyo, Japan). The mean value of the bilateral femoral
neck BMD was used for statistical analysis.
2.3. Serum and urinary bone metabolic markers
The levels of serum PTH-intact and tartrate-resistant acid phospha-
tase-5b (TRACP-5b) were measured by enzyme immunoassay. Serum
homocysteine and hydroxyproline were measured by high-perfor-
mance liquid chromatography. Urinary type 1 collagen N-telopeptide
(NTX) and deoxypyridinoline (DPD) were measured by an enzyme im-
munoassay. The intact amino-terminal pro-peptide of type 1 collagen
(P1NP) was measured by a radioimmunoassay. Serum was collected
and analyzed prior to surgery.t micrographs of a trabecula withminimodeling in a lamina bone in a lumbar spine biopsy
bar spinal canal stenosis. Note that bone surface is covered with osteoid in the formative
imodeling site (right panels). OS, osteoid surface; QS quiescent surface; FMI, formative
line.
Table 3
Structural indices of the surgical specimens.
Ctrl ELD BP p-Value
BV/TV (%) 18.4 ± 5.1 10.8 ± 3.0 17.8 ± 5.4 n.s.
OV/BV (%) 2.07 ± 2.22 1.78 ± 1.22 2.24 ± 3.19 n.s.
Tb.Th (μm) 158.1 ± 43.6 110.0 ± 30.3 123.3 ± 18.8 n.s.
Tb.N 1.17 ± 0.15 1.02 ± 0.26 1.45 ± 0.36 n.s.
Tb.Sp (μm) 713.5 ± 119.7 949.5 ± 301.4 610.5 ± 173.5 n.s.
BV/TV bone volume/tissue volume, OV/BV osteoid volume/bone volume, Tb.Th trabecular
thickness, Tb.N trabecular number, Tb.Sp trabecular separation.
n.s. not signiﬁcant.
Table 1
Baseline demographic subject data.
Group Ctrl ELD BP p-Value
N 6 5 5 –
Age (years) 77.7 ± 8.6 79.2 ± 4.3 80.0 ± 2.9 n.s.
BMI (kg/m2) 23.4 ± 4.4 21.4 ± 3.9 22.9 ± 3.7 n.s.
Diagnosis DS;1, LCS;5 DS;2, LCS;3 LCS;5 n.s.
Surgical method Dec;5, Fus;1 Dec;4, Fus;1 Dec;5 n.s.
Surgery time (min) 94.8 ± 57.7 83.2 ± 49.3 61.2 ± 23.1 n.s.
EBL (g) 166.8 ± 268.6 136.0 ± 146.2 62.0 ± 83.5 n.s.
DEXA
(g/cm2)
Lumbar 0.95 ± 0.09 1.04 ± 0.27 1.12 ± 0.21 n.s.
Femoral neck 0.67 ± 0.18 0.66 ± 0.05 0.73 ± 0.09 n.s.
DEXA
(YAM%)
Lumbar 85.3 ± 8.0 92.6 ± 23.8 99.4 ± 18.6 n.s.
Femoral neck 73.5 ± 18.9 73.3 ± 5.8 81.0 ± 9.3 n.s.
BMI body mass index, EBL estimated blood loss, YAM young adult mean, DS degenerative
spondylolisthesis, LCS lumbar spinal canal stenosis, Dec; decompression, Fus fusion, n.s.
not signiﬁcant.
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Surgical specimens were collected from the lamina of the 4th or 5th
lumbar spine using a bone chisel (6 or 10 mm in width), ﬁxed in 70%
ethanol, and stained with Villanueva bone stain. No histological abnor-
mality suggestive of metabolic bone diseases such as osteomalacia was
found in any of the specimens. A bone histomorphometric analysis was
performed by direct tracing using a digitizer. The histomorphometric
parameters were analyzed using Bone Histomorphometric System soft-
ware (System Supply, Nagano, Japan). Minimodeling sites were identi-
ﬁed by the formation of mineralized bone on a smooth cement line,
which indicates the lack of preceding bone resorption (Frost, 1990;
Kobayashi et al., 2003; Ubara et al., 2005; Yajima et al., 2007).
Minimodeling sites were further grouped into formative and quiescent
minimodeling sites. Formative minimodeling sites were deﬁned as
minimodeling sites with an osteoid surface (Fig. 1). Those sites without
an osteoid surface were deﬁned as quiescent minimodeling sites. The
number and bone volume (BV) of minimodeling sites were measured
in each specimen. The parameters of the bone histomorphometric anal-
ysis are presented according to the standardized nomenclature
(Dempster et al., 2013). All of the histomorphometric analyses were
performed in a blinded manner.2.5. Statistical analysis
The data are presented as the means ± SD. The differences between
the groups were examined by one-way analysis of variance (ANOVA).
When the ANOVA indicated a signiﬁcant difference, statistical differ-
ences between individual groups were evaluated with Tukey's multiple
comparison test. p b 0.05 was considered statistically signiﬁcant.
GraphPad Prism version 6.0 for Windows (GraphPad Software, San
Diego, CA) was used for all of the statistical analyses.Table 2
Serum and urinary biochemical parameters.
Group Ctrl
Serum Ca (mg/dl) 9.2 ± 0.5
IP (mg/dl) 3.7 ± 0.5
PTH (pg/ml) 52.3 ± 23.4
Intact P1NP (μg/L) 51.4 ± 13.1
TRACP-5b (mU/dl) 460.5 ± 151.5#
Urine DPD (nmol BCE/mmol Cr) 10.7 ± 4.3#
NTX (nmol BCE/mmol Cr) 61.4 ± 25.2#
P1NP amino-terminal pro-peptide of type 1 collagen, TRACP-5b tartrate-resistant acid phospha
n.s. not signiﬁcant, # values outside the normal range.3. Results
3.1. Baseline demographic data of the subjects
There were no signiﬁcant differences in the baseline demographic
details between the three groups with respect to age, body mass
index, type of lumbar degenerative disorder, surgical method, surgery
time, estimated blood loss, and BMD of the lumbar and femoral neck
(Table 1). Preoperative symptoms, neurological status, and ADL restric-
tion as assessed by the JOA score (Hirabayashi et al., 1981)were not sig-
niﬁcantly different between these three groups (data not shown).
3.2. Serum and urinary biochemical parameters
The serum P1NP level, a bone formation marker, was signiﬁcantly
higher in the Ctrl group than in the BP group (Table 2). Bone resorption
markers (serum TRACP-5b, urinary DPD, and NTX) in the Ctrl group
were all above the normal range, but they were not signiﬁcantly differ-
ent from those in the ELD and BP groups. These results indicate that
bone turnover was highly enhanced in the Ctrl group, and the high
bone turnover was suppressed in the patients who had been treated
with osteoporosis medications (ELD and BP groups). Therewere no sta-
tistically signiﬁcant differences in the other parameters between the
three groups.
3.3. Bone histomorphometric analysis
Consistent with the BMD data, there were no signiﬁcant differences
in the structural indices between the three groups (Table 3). Osteoblas-
tic and osteoclastic indices tended to have higher values in the Ctrl
group compared with those in the ELD and BP groups, indicating that
bone turnover is enhanced in untreated patients (Table 4). However,
only the Ob.S/OS ratio was signiﬁcantly different between the Ctrl and
BP groups.
Minimodeling sites were identiﬁed in 14 of 16 specimens (88%).
Two specimens that lacked apparent minimodeling sites were found
in the Ctrl and BP groups. Formative minimodeling sites were found in
5 specimens in the Ctrl group (83%), 5 in the ELD group (100%), and 3
in the BP group (60%). Quiescent minimodeling sites were identiﬁedELD BP p-Value
9.0 ± 0.4 9.7 ± 0.4 n.s.
3.6 ± 0.6 3.6 ± 0.5 n.s.
38.2 ± 17.8 39.4 ± 11.9 n.s.
39.8 ± 16.3 23.4 ± 10.1 (Ctrl vs BP) 0.026
376.2 ± 134.7 272.8 ± 132.7 n.s.
6.2 ± 2.1 6.5 ± 1.5 n.s.
45.8 ± 8.6 41.2 ± 40.9 n.s.
tase-5b, DPD deoxypyridinoline, NTX type 1 collagen N-telopeptide.
Table 4
Osteoblastic and osteoclastic indices of the surgical specimens.
Ctrl ELD BP p-value
OS/BS (%) 17.66 ± 17.69 13.34 ± 8.12 13.97 ± 16.84 n.s.
Ob.S/OS (%) 55.96 ± 18.52 34.87 ± 12.28 31.06 ± 6.39 (Ctrl vs BP) 0.036
Ob.S/BS (%) 12.16 ± 14.84 4.43 ± 3.33 3.91 ± 4.11 n.s.
N.Ob/BS
(N/mm)
5.36 ± 5.34 2.41 ± 1.65 2.18 ± 2.04 n.s.
N.Ob/OS
(N/mm)
30.17 ± 8.36 18.72 ± 4.65 20.43 ± 5.27 n.s.
ES/BS (%) 4.81 ± 3.44 4.04 ± 3.99 2.13 ± 2.09 n.s.
Oc.S/BS (%) 0.68 ± 0.70 0.50 ± 0.58 0.25 ± 0.26 n.s.
Oc.S/ES (%) 15.61 ± 13.48 8.32 ± 5.06 9.79 ± 5.24 n.s.
N.Oc/BS
(N/mm)
0.13 ± 0.12 0.12 ± 0.13 0.07 ± 0.06 n.s.
N.Oc/ES
(N/mm)
3.20 ± 2.68 2.41 ± 1.25 4.48 ± 3.31 n.s.
OS/BS osteoid surface/bone surface, Ob.S/OS osteoblast surface/osteoid surface, Ob.S/BS
osteoblast surface/bone surface, N.Ob/BS number of osteoblasts/bone surface, N.Ob/OS
number of osteoblasts/osteoid surface, ES/BS eroded surface/bone surface, Oc.S/ES osteo-
clast surface/eroded surface, Oc.S/BS osteoclast surface/bone surface, N.Oc/BS number of
osteoclasts/bone surface, N.Oc/ES number of osteoclasts/eroded surface.
n.s. not signiﬁcant.
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in the BP group (60%). In addition, we found that bone lacunae in the BP
group specimens were often devoid of osteocytes (Fig. 2). As previously
shown in mice treated with a bisphosphonate (alendronate) (Tsuboi et
al., 2016), this ﬁnding suggests that bisphosphonates not only exhibit a
negative impact on osteoclasts but also on osteocytes in humans.
The number of formative minimodeling sites/BV (N.F.MI/BV) in ELD
group was signiﬁcantly higher than in BP group, whereas, there was no
difference in the number of quiescent minimodeling sites/BV (N.Q.MI/
BV) between these two groups (Fig. 3A). N.F.MI/BV in ELD group wasFig. 2.Minimodeling sites in human specimens. Representative images of trabeculae of a Ctrl pa
images; lower panels, ﬂuorescent images). Inminimodeling, bone is formed on a smooth cemen
upper panels, showing the presence (Ctrl and EDL groups) or absence (BP group) of an osteo
(arrowheads); whereas those lacking osteocytes show very low ﬂuorescence signal (right-lowalso higher than in Ctrl group, but the difference did not reach statistical
signiﬁcance. The formative minimodeling BV/BV (F.MI.BV/BV), which
reﬂects the bone formation activity through minimodeling, in ELD
group was signiﬁcantly higher than in BD or Ctrl group (Fig. 3B). On
the other hand, there was no difference in the quiescent minimodeling
BV/BV (Q.MI.BV/BV) among three groups. Similar trend was also found
in the minimodeling osteoid volume/BV (MI.OS/BV) and in the
formative minimodeling bone volume/the number of formative
minimodeling sites (F.MI.BV/N.F.MI,which reﬂects the bone forming ac-
tivity of each minimodeling sites), where these indices in ELD group
were signiﬁcantly higher than those in BP group (Fig. 3C and D).
Taken together, these observations suggest that the number of
minimodeling sites and bone formation through minimodeling were
enhanced in patients who were treated with ELD, but were suppressed
in those treated with BPs.4. Discussion
Our data showed thatminimodeling is readily observed in the verte-
bral tissues collected from postmenopausal patients, and that the pa-
tients treated with ELD have increased bone formation through
minimodeling compared with those with BPs. These observations sug-
gest that a vitamin D analog ELD and BPs have apparently opposite ef-
fects on minimodeling in vivo, where ELD increases and BPs
suppresses minimodeling-based bone formation. Although it has been
shown that ELD can promote osteoblast differentiation and focal bone
production through minimodeling in rats (de Freitas et al., 2011) and
primates (Saito et al., 2015; Smith et al., 2013), the potential effects of
ELD on minimodeling in humans has remained to be elucidated. The
present study supports the notion that ELD positively regulates
minimodeling in humans, and suggest that ELD improves trabeculartient and patients treatedwith ELD or BP are shown (upper andmiddle panels, bright light
t line (dotted line). Middle panels represent themagniﬁed images of the boxed area in the
cyte in a bone lacuna. Lacunae containing osteocytes show bright red ﬂuorescent signal
er panel). MI, minimodeling. Bars, 30 μm.
Fig. 3. Histomorphometric analysis of minimodeling. Bars indicate means ± SD. *p b 0.05.
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by potentially reducing the risk of fragile fracture.
The concept of minimodeling is not new (Kobayashi et al., 2003;
Takahashi et al., 1964; Frost, 1995); however, controversy still remains
regarding how readily minimodeling occurs under physiological condi-
tions in humans. In rats, a major proportion of bone formation occurs
through minimodeling in their growth period (b6 months old) (Chow
et al., 1993). In humans, Frost et al. showed that 3.3% of cement lines
in the trabecular bone of bone specimens that were collected from
157 healthy human subjects did not exhibit scalloping and hypothe-
sized that focal de novo bone formation (minimodeling) occurs in
humans throughout life (Kobayashi et al., 2003; Takahashi et al., 1964;
Frost, 1995). In agreement, Kobayashi et al. performed in vivo ﬂuoro-
chrome labeling and identiﬁed minimodeling in 63% of the bone speci-
mens that were collected from menopausal patients (Kobayashi et al.,
2003). This study, however, could potentially have underestimated
the number of minimodeling sites becauseminimodeling sites were re-
stricted to newly formed bone siteswithﬂuorochrome incorporation. In
agreement with the observations by Frost and Takahashi (Kobayashi et
al., 2003; Takahashi et al., 1964; Frost, 1995), minimodeling-based bone
formation was identiﬁed in 5 of 6 untreated patients and 86% of all the
patients who were enrolled in the present study. Furthermore, the ex-
tent of minimodeling in our study was comparable with the results of
Kobayashi's study (Kobayashi et al., 2003). Although some studies
have reported the absence of minimodeling-based formation in
human samples (Lindsay et al., 2006; Ma et al., 2006), our data are in
agreement with the idea that minimodeling is not an exceptionally
rare event in postmenopausal osteoporotic patients.
The nature and function of minimodeling are not fully understood.
Previous studies have shown that bone anabolic agents, including PTH,PGE2, and vitamin D analogs, stimulate bone formation through
minimodeling in animals (Zhou et al., 2001; Yao et al., 1999; Saito et
al., 2013) and humans (Lindsay et al., 2006; Ma et al., 2006). In studies
using rodents, it has been shown that vitamin D analog-induced
minimodeling can potentially increase trabecular connectivity (Erben,
2001). Recently, this observation was further conﬁrmed in primates
that were treated with ELD (Saito et al., 2015). Saito et al. showed that
the trabecular connectivity of the lumber vertebra from OVX monkeys
that were treated with ELD showed a higher node-to-node strut length
and a lower terminus-to-terminus strut length compared with those in
non-treated OVX monkeys. Based on these observations, the authors
concluded that ELD treatment leads to an increase in trabecular connec-
tivity in primates andmay improve the biomechanical properties of the
lumbar vertebrae. Although there are no data to support whether this
biomechanical improvement also occurs in humans, it is tempting to
speculate that the enhanced bone formation through minimodeling in
patients who were treated with ELD contributed, at least in part, to
the reduced rate of fracture incidence (Matsumoto et al., 2011).
Unlike other studies that use iliac bone specimens, we used the basal
part of the lamina in thepresent study. Although it is not common to use
the lamina for histomorphometric analysis, we were able to collect in-
tact bone tissues with relative ease. It should also be noted that we
had sampled other posterior parts of the vertebrae in our preliminary
experiments and found thebasal part of the lamina to be the least affect-
ed by the degenerative changes in the vertebrae. Most importantly, be-
cause the specimens were collected from bone tissues that are usually
disposed of after surgery, there was virtually no disadvantage to or bur-
den on the patients who were enrolled in the study.
There are several limitations in the present study. Because osteopo-
rosis medications are often prescribed in combination, relatively few
postmenopausal patients who underwent lumbar surgery were treated
with a single drug in our patient pool. Moreover, lumber degenerative
disorders affect women less frequently than men. For these reasons,
we could only enroll 5–6 eligible patients in each group out of a total
of approximately 150 patients who underwent spinal surgery at our in-
stitute during the study period. Furthermore, the subjects in our study
all had lumbar degenerative disorder, whichmay have indirectly affect-
ed the systemic bonemetabolism due to the decreased physical activity.
Therefore, the results of the present study have to be interpreted with
caution. In addition, we found no statistically signiﬁcant differences in
the bassline BMD among the subject groups, irrespective of the pres-
ence or absence of anti-osteoporotic medication prior to surgery
(Table 1). This could have possibly derived from various factors, includ-
ing the relatively small number of subjects, the relatively short period of
medication usage (please note that ELD became available in 2011 in
Japan), and the differences in the BMD among the patients when the
medication was initiated. Nevertheless, the serum and urinary bio-
chemical parameters were all within the normal range in patients that
had been treated with ELD or BP; whereas, there was an increase in
the values of TRACP-5b, DPD, and NTX in patients without any medica-
tion (Ctrl) (Table 2). The data indicate that the treatmentwith ELD or BP
had been successful and effective in suppressing bone turnover rate, and
supports the efﬁcacy of the treatment in these patients.
In summary, despite the limited number of patients enrolled in the
present study, our data suggest that a vitamin D analog ELD induces
minimodeling-based bone formation in postmenopausal osteoporotic
patients, whereas, BPs have suppressive effects on minimodeling. We
would also like to emphasize herein that the histomorphometric analy-
sis was fully done in a blindmanner so as to eliminate any potential bias
in evaluating the data. Consistent with the hypothesis raised by Frost
and Takahashi (Jee et al., 2007; Kobayashi et al., 2003; Frost, 1995),
our observations indicate that minimodeling is a physiologically rele-
vant event that occurs throughout life. However, the nature and func-
tions of minimodeling in humans remain to be elucidated. Further
clinical investigations are warranted to clarify the physiological role of
minimodeling and its potential contributions in skeletal homeostasis.
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